发布求助
文献互助 智能选刊 最新文献

Personalized medicine最新文献

筛选
英文 中文
Long noncoding RNA polymorphisms in gynecological cancers. 妇科癌症中的长非编码 RNA 多态性。
Personalized medicine Pub Date : 2024-01-01 Epub Date: 2023-12-14 DOI: 10.2217/pme-2023-0082
Esmat Abdi, Saeid Latifi-Navid, Alireza Panahi
{"title":"Long noncoding RNA polymorphisms in gynecological cancers.","authors":"Esmat Abdi, Saeid Latifi-Navid, Alireza Panahi","doi":"10.2217/pme-2023-0082","DOIUrl":"10.2217/pme-2023-0082","url":null,"abstract":"<p><p>Gynecological malignancies are one of the main causes of cancer-induced mortality. Despite remarkable recent therapeutic advances, current therapeutic options are not sufficient. Regarding the effect of long noncoding RNAs (lncRNAs) on cell differentiation, proliferation and apoptosis, variations in their expression cause different anomalies, such as tumorigenesis. SNPs influence lncRNA function and expression. LncRNA polymorphisms can predict cancer risk and are effective for early diagnosis and customized therapy. In this literature review, we comprehensively investigate the effect of lncRNA polymorphisms on gynecological cancers. LncRNA-related variants are proposed to evaluate cancer incidence, early detection and management of personalized therapy. Nonetheless, more studies are required to validate the consistency of current findings in numerous samples and across various ethnic groups.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"59-68"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138816078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing vancomycin therapeutic drug monitoring compliance in pediatric oncology: towards personalized medication management. 优化万古霉素治疗药物监测在儿科肿瘤中的依从性：实现个性化用药管理。
Personalized medicine Pub Date : 2024-01-01 Epub Date: 2024-07-04 DOI: 10.1080/17410541.2024.2360386
Rewan Gamal Mohamed, Rania Saber, Mohamed Ali Hussein, Amira Shalaby, Nouran Yasser, Sherif Kamal, Lobna Shalaby, Mohamed Nagy
{"title":"Optimizing vancomycin therapeutic drug monitoring compliance in pediatric oncology: towards personalized medication management.","authors":"Rewan Gamal Mohamed, Rania Saber, Mohamed Ali Hussein, Amira Shalaby, Nouran Yasser, Sherif Kamal, Lobna Shalaby, Mohamed Nagy","doi":"10.1080/17410541.2024.2360386","DOIUrl":"10.1080/17410541.2024.2360386","url":null,"abstract":"<p><p><b>Aim:</b> Vancomycin, a crucial treatment for Gram-positive bacteria, necessitates therapeutic drug monitoring (TDM) to prevent treatment failures. We investigated the healthcare professional's compliance toward TDM of vancomycin recommendations and follow-up levels. <b>Materials & methods:</b> We collected data from 485 patients who received vancomycin in the Children's Cancer Hospital Egypt 57357 medical records system (Cerner) over 4 months, from January to April 2020. <b>Results:</b> Our data shows that only 54% of patients had TDM requests from healthcare professionals for the total patients who received vancomycin treatment. The healthcare professionals' compliance with the recommendations was 91.7%, while the follow-up levels were 66.7%. <b>Conclusion:</b> While overall adherence to recommendations is strong, enhancing compliance with follow-up levels remains a priority for improvement.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"211-218"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients. CYP2D6基因分型及其对癌症他莫昔芬治疗患者预后的临床影响。
Personalized medicine Pub Date : 2023-11-01 Epub Date: 2023-11-10 DOI: 10.2217/pme-2023-0063
Gabriel Ramírez, Marcelo Vital, Carolina Vergara, Florencia Carusso, Florencia Neffa, Adriana Della Valle, Patricia Esperón
{"title":"<i>CYP2D6</i> genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients.","authors":"Gabriel Ramírez, Marcelo Vital, Carolina Vergara, Florencia Carusso, Florencia Neffa, Adriana Della Valle, Patricia Esperón","doi":"10.2217/pme-2023-0063","DOIUrl":"10.2217/pme-2023-0063","url":null,"abstract":"<p><p><b>Aims:</b> To report the distribution of allele frequencies of <i>CYP2D6</i> gene and to evaluate their influence on the clinical outcomes of a group of breast cancer patients receiving adjuvant tamoxifen treatment from Uruguay. <b>Patients & methods:</b> 199 samples were genotyped through real-time polymerase chain reaction assays. Metabolization profiles were inferred from the genotypes. Correlations were evaluated using Pearson's χ<sup>2</sup> test. <b>Results:</b> Phenotype frequencies were 0.65 normal (NM), 0.30 intermediate (IM) and 0.05 poor metabolizers (PM). Similar clinical outcomes between NM and (PM + IM) patient groups (odds ratio = 1.011, 95% CI = 0.2703-3.7826; p = 0.987) were found. <b>Conclusion:</b> CYP2D6 allele frequencies were analyzed for the first time in a cohort from Uruguay. Results did not support any impact of <i>CYP2D6</i> gene polymorphisms on clinical outcomes.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"477-483"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72016605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
De novo variants of dominant monogenic disorders in Vietnam detected by a noninvasive prenatal test: a case series. 非侵入性产前检测在越南发现的显性单基因疾病的新变异：一个病例系列。
Personalized medicine Pub Date : 2023-11-01 Epub Date: 2023-11-08 DOI: 10.2217/pme-2023-0105
Nhat-Thang Tran, Son Ta Vo, Duy-Anh Nguyen, Canh-Chuong Nguyen, Linh Thuy Dinh, Minh-Thu Thi Tran, Danh-Cuong Tran, Lan-Anh Thi Luong, Kim-Phuong Doan, Vu Quoc Huy Nguyen, Thi Minh Thi Ha, Linh-Giang Thi Truong, Phuong Thi-Mai Cao, Vy Thi-Nhat Tran, Thu Huong Nhut Trinh, Quang Thanh Le, Van Thong Nguyen, Diem-Tuyet Thi Hoang, My-Nhi Ba Nguyen, Chi-Thuong Bui, Son-Tra Thi Tran, Duc-Tam Lam, Hong-Thinh Le, My-Ngoc Ba Nguyen, Viet-Thang Ho, Minh-Trung Nguyen, Trang Thi Dao, Phuong Minh Nguyen, Thu-Hang Le Nguyen, Nhung Phuong Ha, Y-Thanh Lu, Thanh-Thuy Thi Do, Dinh-Kiet Truong, Minh-Duy Phan, Hoai-Nghia Nguyen, Hoa Giang, Hung-Sang Tang
{"title":"<i>De novo</i> variants of dominant monogenic disorders in Vietnam detected by a noninvasive prenatal test: a case series.","authors":"Nhat-Thang Tran, Son Ta Vo, Duy-Anh Nguyen, Canh-Chuong Nguyen, Linh Thuy Dinh, Minh-Thu Thi Tran, Danh-Cuong Tran, Lan-Anh Thi Luong, Kim-Phuong Doan, Vu Quoc Huy Nguyen, Thi Minh Thi Ha, Linh-Giang Thi Truong, Phuong Thi-Mai Cao, Vy Thi-Nhat Tran, Thu Huong Nhut Trinh, Quang Thanh Le, Van Thong Nguyen, Diem-Tuyet Thi Hoang, My-Nhi Ba Nguyen, Chi-Thuong Bui, Son-Tra Thi Tran, Duc-Tam Lam, Hong-Thinh Le, My-Ngoc Ba Nguyen, Viet-Thang Ho, Minh-Trung Nguyen, Trang Thi Dao, Phuong Minh Nguyen, Thu-Hang Le Nguyen, Nhung Phuong Ha, Y-Thanh Lu, Thanh-Thuy Thi Do, Dinh-Kiet Truong, Minh-Duy Phan, Hoai-Nghia Nguyen, Hoa Giang, Hung-Sang Tang","doi":"10.2217/pme-2023-0105","DOIUrl":"10.2217/pme-2023-0105","url":null,"abstract":"<p><p><b>Background:</b> Noninvasive prenatal tests for monogenic diseases (NIPT-SGG) have recently been reported as helpful in early-stage antenatal screening. Our study describes the clinical and genetic features of cases identified by NIPT-SGG. <b>Materials & methods:</b> In a cohort pregnancy with abnormal sonograms, affected cases were confirmed by invasive diagnostic tests concurrently, with NIPT-SGG targeting 25 common dominant single-gene diseases. <b>Results:</b> A total of 13 single-gene fetuses were confirmed, including Noonan and Costello syndromes, thanatophoric dysplasia, achondroplasia, osteogenesis imperfecta and Apert syndrome. Two novel variants seen were tuberous sclerosis complex (<i>TSC2</i> c.4154G>A) and Alagille syndrome (<i>JAG1</i> c.3452del). <b>Conclusion:</b> NIPT-SGG and standard tests agree on the results for 13 fetuses with monogenic disorders. This panel method of screening can benefit high-risk Vietnamese pregnancies, but further research is encouraged to expand on the causative gene panel.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"467-475"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IL-6 gene polymorphism predicts PEGylated IFN-α treatment response in hepatitis B surface antigen-positive chronic hepatitis B patients. IL-6基因多态性预测乙型肝炎表面抗原阳性慢性乙型肝炎患者聚乙二醇化IFN-α治疗反应。
Personalized medicine Pub Date : 2023-11-01 DOI: 10.2217/pme-2023-0089
Xiaoqing Wang, Xiu Gu, Fengli Liu
{"title":"<i>IL-6</i> gene polymorphism predicts PEGylated IFN-α treatment response in hepatitis B surface antigen-positive chronic hepatitis B patients.","authors":"Xiaoqing Wang, Xiu Gu, Fengli Liu","doi":"10.2217/pme-2023-0089","DOIUrl":"10.2217/pme-2023-0089","url":null,"abstract":"<p><p><b>Background:</b> Genetic polymorphism can affect the response to antiviral therapy of chronic hepatitis B (CHB) patients. <b>Objective:</b> The study examined the genetic association of the <i>IL-6</i> rs1800796 polymorphism with PEGylated IFN-α (PegIFN-α) treatment response in hepatitis B surface antigen (HBsAg)-positive CHB patients. <b>Methods:</b> Direct sequencing was done for the genotyping of the rs1800796 polymorphism in the serum of CHB patients. <b>Results:</b> More patients with combined response (n = 95) carried <i>IL-6</i> rs1800796 GC genotypes, while CC genotype carriers possessed reduced HBeAg seroconversion rate and high values of hepatitis B virus DNA. Baseline HBsAg and HBeAg and <i>IL-6</i> rs1800796 CC genotype were independently related to PegIFN-α treatment response. <b>Conclusion:</b> Detection of the <i>IL-6</i> rs1800796 genotype in CHB patients may have potential guiding significance for PegIFN-α response.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"503-510"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA polymorphisms and lung cancer risk. LncRNA多态性与癌症风险。
Personalized medicine Pub Date : 2023-11-01 Epub Date: 2023-11-02 DOI: 10.2217/pme-2023-0081
Esmat Abdi, Saeid Latifi-Navid, Alireza Panahi, Hamid Latifi-Navid
{"title":"LncRNA polymorphisms and lung cancer risk.","authors":"Esmat Abdi, Saeid Latifi-Navid, Alireza Panahi, Hamid Latifi-Navid","doi":"10.2217/pme-2023-0081","DOIUrl":"10.2217/pme-2023-0081","url":null,"abstract":"<p><p>Lung cancer (LC) imposes a significant burden, and is associated with high mortality and morbidity among malignant tumors. Aberrant expression of particular lncRNAs is closely linked to LC. LncRNA polymorphisms cause abnormal expression levels and/or structural dysfunction. They can affect the progression of cancer, survival, response to chemotherapy and recurrence rates in cancer patients. The present article provides a comprehensive overview of the effect of lncRNA genetic polymorphisms on LC. It is proposed that lncRNA-related variants can be used to predict cancer risk and therapeutic outcomes. More large-scale trials on diverse ethnic groups are required to validate the results, thus personalizing LC therapy based on lncRNA genotypes.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"511-522"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A real-world analysis of tyrosine receptor kinase inhibitor-related toxicities in cancer treatment. 癌症治疗中酪氨酸受体激酶抑制剂相关毒性的现实世界分析。
Personalized medicine Pub Date : 2023-11-01 DOI: 10.2217/pme-2023-0072
Wenjie Li, Keshan Wen, Weijie Zhu, Shangfei Luo
{"title":"A real-world analysis of tyrosine receptor kinase inhibitor-related toxicities in cancer treatment.","authors":"Wenjie Li, Keshan Wen, Weijie Zhu, Shangfei Luo","doi":"10.2217/pme-2023-0072","DOIUrl":"10.2217/pme-2023-0072","url":null,"abstract":"<p><p><b>Background:</b> This study analyzed real-world data from 2004 to 2023 to evaluate the toxicity profile of tyrosine receptor kinase (TRK) inhibitor therapy. <b>Method:</b> A retrospective analysis of US FDA Adverse Event Reporting System data was conducted to identify adverse events in patients receiving TRK inhibitor therapy. <b>Result:</b> Entrectinib demonstrated toxicities primarily in the cardiovascular and nervous systems, followed by the renal and urinary system. Common adverse effects included dizziness, renal impairment, constipation, heart failure and taste disorders. Larotrectinib induced adverse events mainly in the hepatobiliary and nervous systems, with peripheral neuropathy, myalgia, renal impairment and increased alanine aminotransferase commonly reported. <b>Conclusion:</b> Careful monitoring and supportive care strategies are essential for managing adverse events associated with TRK inhibitor therapy.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"485-491"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low rate of complications in nipple-sparing mastectomy for patients with BRCA1 and BRCA2 mutation. BRCA1和BRCA2突变患者保留乳头乳房切除术并发症发生率低。
Personalized medicine Pub Date : 2023-11-01 DOI: 10.2217/pme-2023-0084
Antônio Luiz Frasson, Ana Beatriz Falcone, Fernanda Barbosa, Alessandra Borba Anton de Souza, Carolina Malhone, Isabela Miranda, Betina Vollbrecht, Monica Adriana Rodriguez Martinez Frasson, Luiza Kobe, Martina Lichtenfels
{"title":"Low rate of complications in nipple-sparing mastectomy for patients with <i>BRCA1</i> and <i>BRCA2</i> mutation.","authors":"Antônio Luiz Frasson, Ana Beatriz Falcone, Fernanda Barbosa, Alessandra Borba Anton de Souza, Carolina Malhone, Isabela Miranda, Betina Vollbrecht, Monica Adriana Rodriguez Martinez Frasson, Luiza Kobe, Martina Lichtenfels","doi":"10.2217/pme-2023-0084","DOIUrl":"10.2217/pme-2023-0084","url":null,"abstract":"<p><p><b>Background:</b> To describe the indications and outcomes of <i>BRCA</i> mutation carriers undergoing nipple-sparing mastectomy (NSM). <b>Methods:</b> In this retrospective study, 76 <i>BRCA</i> mutation carriers with no cancer who opted to undergo risk reduction NSM or diagnosed with breast cancer (BC) who opted to undergo therapeutic NSM were included. <b>Results:</b> Indications for NSM: cancer treatment (n = 33), bilateral risk reduction (n = 39) and contralateral prophylactic NSM (n = 4). In a mean follow-up of 45 months (median: 30 months), one patient (2.5%) undergoing risk-reducing NSM developed a new BC. One (3%) local, one (3%) ipsilateral axillary and one (3%) distant recurrence were observed in BC patients. No partial or total nipple necrosis occurred. <b>Conclusion:</b> NSM is safe for reducing the risk of BC development in <i>BRCA</i> mutation carriers and for treating cancer.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"493-501"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalized medicine, the inevitable future of cancer immunotherapy. 个性化医疗，癌症免疫治疗的必然未来。
Personalized medicine Pub Date : 2023-09-01 Epub Date: 2023-10-06 DOI: 10.2217/pme-2023-0083
Mohsen Basiri
{"title":"Personalized medicine, the inevitable future of cancer immunotherapy.","authors":"Mohsen Basiri","doi":"10.2217/pme-2023-0083","DOIUrl":"10.2217/pme-2023-0083","url":null,"abstract":"","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"413-416"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41169949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of CYP2C9*2 and *3 polymorphisms on valproate-associated adverse drug reactions in individuals living with epilepsy: a case-control study. CYP2C9*2和*3多态性对癫痫患者丙戊酸钠相关药物不良反应的影响：一项病例对照研究。
Personalized medicine Pub Date : 2023-09-01 Epub Date: 2023-10-09 DOI: 10.2217/pme-2023-0033
Kirubakaran Ramakrishnan, Ramasamy Kesavan, Shravan Venkatraman, Sunil K Narayan, Ramachandran Ramesh Kumar, Deepak Shewade
{"title":"Impact of <i>CYP2C9*2</i> and <i>*3</i> polymorphisms on valproate-associated adverse drug reactions in individuals living with epilepsy: a case-control study.","authors":"Kirubakaran Ramakrishnan,&nbsp;Ramasamy Kesavan,&nbsp;Shravan Venkatraman,&nbsp;Sunil K Narayan,&nbsp;Ramachandran Ramesh Kumar,&nbsp;Deepak Shewade","doi":"10.2217/pme-2023-0033","DOIUrl":"10.2217/pme-2023-0033","url":null,"abstract":"<p><p>Epilepsy is characterized by repeated seizure activity. Valproate, a commonly used antiepileptic drug, shows large inter-individual variation in plasma valproic levels and causes many adverse drug reactions. <b>Aim:</b> To find the influence of <i>CYP2C9*2</i> and <i>*3</i> polymorphisms on valproate-associated adverse drug reactions and plasma valproic acid levels in people with epilepsy. <b>Methods:</b> We recruited 158 people with epilepsy (79 cases and 79 controls) from an epilepsy clinic. Steady-state plasma valproic acid levels were measured using liquid chromatography-mass spectrometry and genotyping of <i>CYP2C9</i> variants was carried out with helps of RT-PCR. <b>Results:</b> The presence of a mutant heterozygous genotype showed an odds ratio (OR) of 2.82 (95% CI: 1.10-7.24) and the adjusted OR was 5.39 (95% CI: 1.69-17.16). There was no significant difference in steady-state plasma valproate concentration between genotypes. <b>Conclusion:</b> The presence of a mutant heterozygous <i>CYP2C9</i> genotype possesses five-times the risk of developing adverse drug reactions to valproate in people with epilepsy.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"417-424"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信